Verona Pharma plc (VRNA), a biopharmaceutical company, Tuesday announced that the company expects preliminary unaudited fourth quarter net product sales of $36 million and full year sales of $42 million. The sales are from Ohtuvayre, that got approved by FDA in June 26, 2024.
The company expects to expand Ohtuvayre further in 2025.According to Verona, more than 3,500 unique healthcare professionals have prescribed Ohtuvayre. More than 16,000 prescriptions were filled, while approximately one-third of which were patient refills.
The company said it has raised $100 million through the sale of its ordinary shares in the form of ADSs under its 'at-the-market' equity offering program with Jefferies. The shares were sold at an average price of $39.35 per ADS, equivalent to $4.92 per ordinary share.
In the pre-market trading, VRNA is 0.69% less at $44.50 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.